- Home
- Publications
- Publication Search
- Publication Details
Title
Saxagliptin overview: special focus on safety and adverse effects
Authors
Keywords
-
Journal
Expert Opinion On Drug Safety
Volume 12, Issue 1, Pages 103-109
Publisher
Informa Healthcare
Online
2012-11-09
DOI
10.1517/14740338.2013.741584
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin
- (2012) Anthony H. Barnett et al. CURRENT MEDICAL RESEARCH AND OPINION
- Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment
- (2012) André J Scheen Expert Opinion on Drug Metabolism & Toxicology
- The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naive patients with type 2 diabetes mellitus: a randomized controlled trial
- (2012) Robert Frederich et al. Diabetology & Metabolic Syndrome
- Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Saxagliptin
- (2011) David W. Boulton et al. CLINICAL PHARMACOKINETICS
- Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials
- (2011) Matteo Monami et al. CURRENT MEDICAL RESEARCH AND OPINION
- Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment
- (2011) M. Nowicki et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of saxagliptin in drug-naïve Asian patients with type 2 diabetes mellitus: a randomized controlled trial
- (2011) Chang Yu Pan et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Pharmacology of Dipeptidyl Peptidase-4 Inhibitors
- (2011) Roberta Baetta et al. DRUGS
- Efficacy and Safety of Saxagliptin Combination Therapy in US Patients with Type 2 Diabetes
- (2011) Chetan Karyekar et al. POSTGRADUATE MEDICINE
- Dipeptidylpeptitase-4 Inhibitors (Gliptins)
- (2010) André J. Scheen CLINICAL PHARMACOKINETICS
- Glycated Hemoglobin and the Risk of Kidney Disease and Retinopathy in Adults With and Without Diabetes
- (2010) E. Selvin et al. DIABETES
- Pharmacokinetics of dipeptidylpeptidase-4 inhibitors
- (2010) A. J. Scheen DIABETES OBESITY & METABOLISM
- Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial
- (2010) B. Göke et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis
- (2010) S. S. Engel et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial
- (2010) Richard M Bergenstal et al. LANCET
- A Meta-Analysis of Placebo-Controlled Clinical Trials Assessing the Efficacy and Safety of Incretin-Based Medications in Patients with Type 2 Diabetes
- (2010) Walid K.H. Fakhoury et al. PHARMACOLOGY
- A Systematic Assessment of Cardiovascular Outcomes in the Saxagliptin Drug Development Program for Type 2 Diabetes
- (2010) Robert Frederich et al. POSTGRADUATE MEDICINE
- Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes
- (2010) Debora Williams-Herman et al. BMC Endocrine Disorders
- Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes
- (2009) J. Rosenstock et al. CURRENT MEDICAL RESEARCH AND OPINION
- Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide
- (2009) David D. Dore et al. CURRENT MEDICAL RESEARCH AND OPINION
- The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone
- (2009) R. A. DeFronzo et al. DIABETES CARE
- Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial
- (2009) M. Jadzinsky et al. DIABETES OBESITY & METABOLISM
- Pharmacokinetics of the Dipeptidyl Peptidase 4 Inhibitor Saxagliptin in Rats, Dogs, and Monkeys and Clinical Projections
- (2009) A. Fura et al. DRUG METABOLISM AND DISPOSITION
- Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial
- (2009) A. R. Chacra et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Saxagliptin Added to a Thiazolidinedione Improves Glycemic Control in Patients with Type 2 Diabetes and Inadequate Control on Thiazolidinedione Alone
- (2009) Priscilla Hollander et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?
- (2009) Roger Yazbeck et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited
- (2008) B. F. Burkey et al. DIABETES OBESITY & METABOLISM
- Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes
- (2008) J. Rosenstock et al. DIABETES OBESITY & METABOLISM
- Diabetic nephropathy: Important pathophysiologic mechanisms
- (2008) G. Soldatos et al. DIABETES RESEARCH AND CLINICAL PRACTICE
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started